PDE2A Activators
PDE2A activators represent a diverse group of compounds that exert their activating effects on the phosphodiesterase enzyme PDE2A through intricate signaling pathways. Caffeine, a direct activator, modulates the cAMP signaling pathway by inhibiting PDE3, leading to increased intracellular cAMP levels. This elevation in cAMP levels activates PDE2A, creating a positive feedback loop that enhances its hydrolytic activity on cAMP, showcasing the direct activation mechanism. In addition to direct activators, compounds like Vinpocetine act indirectly through the cGMP signaling pathway. By inhibiting PDE1, Vinpocetine prevents the breakdown of cGMP, leading to increased PKG activity, subsequently activating PDE2A. This indirect activation occurs through the cGMP/PKG pathway, highlighting the intricate interplay between different cyclic nucleotide signaling pathways in regulating PDE2A activity.
Furthermore, Fasudil, an indirect activator, modulates PDE2A through the ROCK signaling pathway. Inhibiting ROCK disrupts downstream signaling events, influencing the phosphorylation cascade that regulates PDE2A expression. This indirect activation occurs at the transcriptional level, where Fasudil interferes with the activation of transcription factors involved in PDE2A gene expression, resulting in increased mRNA levels and subsequent upregulation of PDE2A protein expression. These examples illustrate the diverse mechanisms employed by PDE2A activators, underscoring the complexity of PDE2A regulation. The collective understanding of these chemical activators contributes to a nuanced comprehension of the intricate regulatory network governing PDE2A expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine serves as a direct activator of PDE2A by modulating the cAMP signaling pathway. Acting as a phosphodiesterase inhibitor, it prevents the breakdown of cAMP, leading to increased intracellular cAMP levels. Elevated cAMP levels, in turn, activate PDE2A, promoting its hydrolytic activity on cAMP, and resulting in a positive feedback loop that enhances PDE2A activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram acts as a direct activator of PDE2A through its inhibition of PDE4, leading to increased cAMP levels. PDE4 and PDE2A share the substrate cAMP, and inhibiting PDE4 by Rolipram prevents cAMP degradation, indirectly promoting PDE2A activation. This occurs through a competition for cAMP, where decreased PDE4 activity results in elevated cAMP availability for PDE2A, enhancing its hydrolytic activity and overall activation. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine serves as an indirect activator of PDE2A by influencing the cGMP signaling pathway. Acting as a phosphodiesterase inhibitor, Vinpocetine inhibits PDE1, preventing the breakdown of cGMP. Elevated cGMP levels lead to increased PKG activity, which subsequently activates PDE2A. This indirect activation occurs through the cGMP/PKG pathway, where Vinpocetine-mediated inhibition of PDE1 results in enhanced PDE2A activation and modulation of cAMP levels. | ||||||
Enoximone | 77671-31-9 | sc-252775 sc-252775A | 10 mg 50 mg | $181.00 $728.00 | 1 | |
Enoximone acts as a direct activator of PDE2A through the inhibition of PDE3. By inhibiting PDE3, Enoximone prevents the breakdown of cAMP, leading to increased intracellular cAMP levels. Elevated cAMP levels, in turn, activate PDE2A, promoting its hydrolytic activity on cAMP, and resulting in a positive feedback loop that enhances PDE2A activation. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone serves as a direct activator of PDE2A by inhibiting PDE3. Through the inhibition of PDE3, Milrinone prevents the breakdown of cAMP, leading to increased intracellular cAMP levels. Elevated cAMP levels activate PDE2A, promoting its hydrolytic activity on cAMP, resulting in a positive feedback loop that enhances PDE2A activation. | ||||||
Piclamilast | 144035-83-6 | sc-478653 | 5 mg | $300.00 | ||
Piclamilast acts as a direct activator of PDE2A through the inhibition of PDE4. By inhibiting PDE4, Piclamilast prevents the breakdown of cAMP, leading to increased intracellular cAMP levels. Elevated cAMP levels activate PDE2A, promoting its hydrolytic activity on cAMP, resulting in a positive feedback loop that enhances PDE2A activation. | ||||||
Ibudilast | 50847-11-5 | sc-203080 | 10 mg | $218.00 | 1 | |
Ibudilast acts as a direct activator of PDE2A through the inhibition of PDE4. By inhibiting PDE4, Ibudilast prevents the breakdown of cAMP, leading to increased intracellular cAMP levels. Elevated cAMP levels activate PDE2A, promoting its hydrolytic activity on cAMP, resulting in a positive feedback loop that enhances PDE2A activation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast serves as a direct activator of PDE2A by inhibiting PDE5. Through the inhibition of PDE5, Zaprinast prevents the breakdown of cGMP, leading to increased intracellular cGMP levels. Elevated cGMP levels activate PKG, which subsequently activates PDE2A. This direct activation occurs through the cGMP/PKG pathway, where Zaprinast-mediated inhibition of PDE5 results in enhanced PDE2A activation and modulation of cAMP levels. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline acts as a direct activator of PDE2A by inhibiting PDE3. Through the inhibition of PDE3, Theophylline prevents the breakdown of cAMP, leading to increased intracellular cAMP levels. Elevated cAMP levels activate PDE2A, promoting its hydrolytic activity on cAMP, resulting in a positive feedback loop that enhances PDE2A activation. This direct activation occurs through the inhibition of PDE3, allowing PDE2A to exert its regulatory effects on cAMP levels. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR acts as an indirect activator of PDE2A through the AMPK signaling pathway. Activating AMPK, AICAR leads to the inhibition of mTORC1, a known negative regulator of PDE2A expression. This indirect activation occurs at the translational level, where decreased mTORC1 activity results in enhanced PDE2A protein synthesis and stability, ultimately promoting its expression and activation. | ||||||